| Literature DB >> 33288843 |
Shiqin Liu1,2, Michelle Shen1,2, En-Chi Hsu1,2, Chiyuan Amy Zhang3, Fernando Garcia-Marques1,2, Rosalie Nolley3, Kashyap Koul1,2, Meghan A Rice1,2, Merve Aslan1,2, Sharon J Pitteri1,2, Charlie Massie4,5,6, Anne George5, James D Brooks2,3, Vincent J Gnanapragasam7,8, Tanya Stoyanova9,10.
Abstract
Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low risk); CPG5 (high risk) and metastatic disease were analysed using Olink Proteomics panels. Tissue validation was performed by immunohistochemistry in a radical prostatectomy cohort (n = 234). We discovered that nine proteins (pleiotrophin (PTN), MK, PVRL4, EPHA2, TFPI-2, hK11, SYND1, ANGPT2, and hK14) were elevated in metastatic PC patients when compared to other groups. PTN levels were increased in serum from men with CPG5 compared to benign and CPG1. High tissue PTN level was an independent predictor of biochemical recurrence and metastatic progression in low- and intermediate-grade disease. These findings suggest that PTN may represent a novel biomarker for the presence of poor prognosis local disease with the potential to metastasise warranting further investigation.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33288843 PMCID： PMC7921397 DOI： 10.1038/s41416-020-01200-0
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640